InMed appoints Neil Klompas to board, effective October 9, 2025

InMed Pharmaceuticals Inc.

Neil Klompas, CPA, CA, appointed to Board; board size increased to 5 members.
Klompas brings 30+ years experience; was President/COO and CFO at Zymeworks (NASDAQ: ZYME), led 2017 IPO.
Currently CEO of Augerex Life Science Corp, serves on boards of NervGen Pharma (TSXV: NGEN) and HTuO Biosciences.
He will receive standard non-employee director compensation: US$50k annual retainer plus potential committee fees.
No related party transactions or family relationships with any director or officer.

item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.